VITAFLO USA LLC
ALEXANDRIA, VA

Formed in 2011, Nestlé Health Science is the first of a new breed of health-science company. Advancing the therapeutic role of nutrition to change the course of health management for consumers, patients, doctors, nurses and our partners in healthcare: this is our focus. Through investing in innovation and leveraging leading edge science, we are striving to forge a new industry of innovative nutritional therapies with quality of life benefits and proven clinical and health economic value. We are a global company, headquartered in Epalinges (near Lausanne), Switzerland, and employing around 3,000 people worldwide. Founded on the HealthCare Nutrition business of the Nestlé Group, we are building upon firm foundations. We produce science-based nutritional solutions that are available through retail and pharmacy outlets (Consumer Care) or by healthcare professionals in institutions (Medical Nutrition), addressing a spectrum of ages and health conditions from pediatric allergy to malnutrition amongst the frail elderly. We are investing and innovating rapidly in transformational technology platforms and advances that will create what we term Novel Therapeutic Nutrition. It’s about discovering and extending nutrition’s therapeutic role from targeting nutritional gaps/needs associated with particular health conditions, to bring forward products with a more direct therapeutic impact. By harnessing scientific and clinical advances, and bringing forward innovations addressing unmet and underserved needs in new effective and cost-effective ways, we are forging a more integral role for nutrition in health management. External focus is key to this quest, and we have already made some key acquisitions and investment moves to enhance our capabilities and innovation potential. See chapter “Key Investments”. With proprietary access to the research of Nestlé Institute of Health Sciences, set-up simultaneously with our own company, and the taste and nutritional expertise of the Nestlé Group to draw upon – we are well positioned to fulfill our ambitions through innovative nutritional therapies. “Nestlé Health Science is a company on a mission and on the move leading a nutritional innovation frontier across Consumer Care, Medical Nutrition and Novel Therapeutic Nutrition. We are motivated by the opportunity to forge a major therapeutic role for nutrition in the management of health, generating value for people, patients, healthcare professionals and the healthcare systems as a whole. We are seizing the opportunities ahead of us. We are not only innovating and building upon our existing consumer and medical nutrition portfolio, but also investing in and collaborating with entrepreneurial biotech companies to help bring to market transformational therapies, in fields such as the microbiome and amino acids. Our pipeline is strong and balanced across each of our business areas. We have over 3,000 colleagues around the world who are incredibly proud of the role we play in healthcare today, as well as excited by the potential of tomorrow. We are building a new pillar of growth for the Nestlé Group, playing a key role in our parent company’s Nutrition, Health and Wellness strategy, while committed to the purpose of ‘Enhancing the quality of life and contributing to a better future’. Our aim is to be recognized as the world’s leading nutritional therapy company. By exploring and harnessing the power of nutrition to change the course of health we are making a difference to peoples’ health status and quality of life and are on an inspiring journey with all of our stakeholders. Together, let’s succeed.” The acquisition of Vitaflo – headquartered in Liverpool, UK – has enabled Nestlé Health Science to establish a foothold in the fast-growing market for uniquely formulated products that address various congenital metabolic disorders that become apparent only shortly after birth. Vitaflo’s nutritional solutions help patients maintain or recover metabolic homeostasis, often playing the most important role in the management of the disorder. Developing products that taste good, and that are easy and convenient to use, is an important factor in promoting compliance with these highly restrictive dietary management protocols, which are always administered under medical supervision. The company is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is primarily focused on the detection, diagnosis and treatment of disorders within the fields of gastroenterology and oncology. Its strategy includes the marketing and delivery of pharmaceutical products and is complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Nestlé Health Science aims to provide physicians with more targeted solutions to optimize care for their patients. Nestlé Health Science has entered into a staged, milestone-based acquisition of Phagenesis, a UK-based company developing Phagenyx®, an innovative pharyngeal electrical stimulation device to treat dysphagia (swallowing difficulty). Seres Ecobiotic® therapeutic product candidates are based upon microbial organisms, fundamentally different from traditional drugs. Advances in genomics are progressively revealing the importance of the microbiome, which comprise around 100 trillion microorganisms that live in the body, to various aspects of health. Strategic Innovation Partnership with Flagship Ventures Nestlé Health Science has entered into a strategic innovation partnership with Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability based in Cambridge, Mass., USA. Nestlé Health Science has invested in the Flagship Ventures Fund V. The partnership will focus on supporting start-up ventures working on nutritional health and therapy, and is intended to provide Nestlé Health Science with early exposure to Flagship’s innovative insights and technologies, which may be further exploited through minority direct investments, licensing, joint ventures or acquisitions by Nestlé Health Science. .AstraZeneca and Bayer CropScience are also strategic innovation partners in the fund. A significant portion of the partnership’s funding is dedicated to investing in entrepreneurial companies developing breakthrough technologies in the novel nutritional therapy arena relevant to Nestlé Health Science, including brain, gastrointestinal and metabolic health.